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PERSPECTIVES IN BASIC SCIENCE
Macrophages and progressive tubulointerstitial disease
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Macrophages and progressive tubulointerstitial disease. In
chronic renal disease, tubulointerstitial inflammation and injury
is associated with infiltrating macrophages. As a consequence
of primary injury, proteinuria, chronic hypoxia, and glomerular-
derived cytokines may all differentially modulate the expression
of factors that promote macrophage recruitment. In addition to
adhesion molecules and chemokines, products of complement
system and renin-angotensin system activation may direct this
process. Once present at interstitial sites, macrophages inter-
act with resident cells and extracellular matrix to generate a
proinflammatory microenvironment that amplifies tissues in-
jury and promotes scarring. There is now increasing evidence
for the efficacy of interventions directed against factors that
recruit, activate, or are produced by macrophages. A detailed
understanding of the biology of this area may lead to the fur-
ther development of therapies that will improve the outcome
of renal disease.
Over 30 years ago, Risdon et al first described the as-
sociation between the degree of renal impairment and
the extent of tubulointerstitial damage in patients with
glomerular disease [1]. Subsequent studies have shown
that this relationship is a major determinant of progres-
sion to end-stage renal failure (ESRF), and that inter-
stitial inflammation has a central role in this process.
As the interstitial macrophage is involved in both the
initiation and continuation of this inflammatory response,
a detailed knowledge of the role of these cells in situ
may lead to the development of new treatments. Here
we review our current understanding of the mechanisms
that recruit monocytes to the interstitium, how interac-
tions between the differentiated macrophage and other
components of the local microenvironment promote pro-
gressive injury, and how current and future therapies
may modulate these processes. For the purpose of this
review, both monocytes and differentiated interstitial
macrophages will be denoted by Mφ.
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PRIMARY INJURY AND SECONDARY DISEASE
Tubulointerstitial (TI) disease is common to all chronic
progressive renal diseases, irrespective of the initial trig-
ger or site of injury. It is characterized by inflammatory
cell infiltrates, loss of peritubular capillaries, atrophy of
tubules, and interstitial scarring. The extent of disease
on renal biopsy inversely correlates with renal function
and accurately predicts renal prognosis [2]. Morphome-
tric studies indicate that glomerular and tubulointersti-
tial injury is interdependent: thus, in glomerulonephritis,
damage of a single nephron may progress from initial
glomerular injury to peritubular and interstitial inflam-
mation, tubular atrophy, and interstitial scarring [2]. This
local inflammatory response may then involve adjacent
tubules and so initiate or potentiate upstream glomerular
injury. As damage progresses, remaining glomeruli com-
pensate through the development of capillary hyperten-
sion, and glomerulosclerosis develops independent of the
primary injury (reviewed in [3]). Thus, nephron loss as a
consequence of secondary interstitial inflammation may
progress to ESRF. A prominent feature throughout this
process is the presence of leukocytes at sites of injury.
LEUKOCYTES AND INTERSTITIAL
INFLAMMATION
In the normal kidney there are small numbers of inter-
stitial leukocytes. These are predominantly Mφ, although
T cells are also present. In human glomerular disease
there are increased numbers of Mφ and T cells at inter-
stitial sites; most studies report that T cells predominate,
and the majority of these are CD4+, although there is
considerable variation between these analyses (Table 1).
These results should be interpreted with caution, how-
ever, as Mφ enumeration in these studies was performed
by immunohistochemistry (IHC) with primary antibodies
directed against the surface antigen CD14. As the expres-
sion of this antigen varies with the maturity and activation
status of the cell, Mφ numbers have probably been un-
derestimated.
Only a small fraction of leukocytes in the normal kid-
ney comprise B cells, natural killer (NK) cells, and neu-
trophils. In disease states they represent less than 10% of
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Table 1. Interstitial Mφ and T-cell ratios in renal disease: Published
series with 10+ patients
Nephropathy
(Patient number) Reference T cell: Mφ CD4: CD8
Lupus (35) [4] 1.5 1.5
IgA (34) [5] 0.9 2.1
Non-cresc IgA (18) [6] 2.4 1.4
Cresc IgA (5) 1.1 1.3
Memb (13) [7] 2.8 0.5
FGS (13) 1.4 1.9
DN (9) 4 1
IgA (18) 2.4 1.4
Lupus (13) 2.7 1.9
Cresc GN (14) 2.9 1
MPGN (8) 2.6 1.4
FPGN (10) 3 1.2
Memb (36) [8] 0.8 2.2
MPGN (17) [9] 5.1 –
Cresc GN (9) [10] 16 2
FGS (11) 9.1 1.4
MPGN (7) 3.8 1.6
Cresc GN (3) [11] 1.1 1.5
Lupus (7) 0.8 1.3
Abbreviations are: Cresc, crescentic; Memb, membranous nephropathy; FGS,
focal glomerulosclerosis; DN, diabetic nephropathy; MPGN, membranoprolifer-
ative glomerulonephritis; FPGN, focal proliferative glomerulonephritis. Ratios
extrapolated from published data where cell numbers had been expressed as
number per mm2 tissue viewed.
total infiltrating cells, although in proliferative glomeru-
lonephritides, this proportion may be higher [7, 10].
Studies in animal models indicate that Mφare the dom-
inant infiltrating cell in the initiation and progression of
injury in chronic renal disease (reviewed in [12]). Strate-
gies that limit disease progression in his setting include:
(1) the systemic depletion of Mφ; (2) inhibition of proin-
flammatory cytokines that both activate and are produced
by activated Mφ; and (3) the blocking of factors that pro-
mote the recruitment of Mφ to tissue sites. While T cells
almost certainly have an important role in progressive in-
jury in situ in chronic TI disease, this has not been clearly
defined to date, and factors that promote their recruit-
ment and activation require further investigation. The
use of T-cell–deficient mice in a number of models of
progressive renal disease did not, however, prevent the
development of renal injury [13–15].
MACROPHAGE-INDUCED
TUBULOINTERSTITIAL INJURY
Resident and infiltrating Mφ play a central role in in-
nate immune protection both through the clearance of
infective pathogens and through the repair of tissue in-
jury that occurs, in part, as a consequence of this response.
For example, the initial response of Mφ to bacterial infec-
tion is cytotoxic and proinflammatory; then, on control of
the infection, Mφ phagocytoze cellular debris and apop-
totic bodies and begin tissue repair. However, in many

















Fig. 1. Secretory products of activated interstitial macrophages that
may promote tubular atrophy, scar formation, and peritubular capillary
loss in secondary tubulointerstitial disease.
although the primary cause may abate, interstitial inflam-
mation and TI injury worsens [12].
Direct damage to resident cells is caused through the
generation by Mφ of radical oxygen species (ROS), nitric
oxide (NO), complement factors, and proinflammatory
cytokines ([12]; see Fig. 1). Mφ can also affect supporting
matrix and vasculature through the expression of metal-
loproteinases and vasoactive peptides. Resident intersti-
tial fibroblasts and myofibroblasts proliferate in response
to Mφ-derived profibrogenic cytokines, and their number
correlates with the subsequent formation of a scar and
renal decline [16]. These cells are a primary source of
the extracellular matrix (ECM) proteins that accumulate
to form a scar. They may be derived from transdiffer-
entiated tubular epithelial cells, a process promoted by
profibrogenic cytokines, including transforming growth
factor-b (TGF-b) expressed by Mφ, and also by tubu-
lar epithelial cells as a consequence of Mφ-tubular cell
interactions (reviewed in [17]). The role of TGF-b has
been studied in detail. It promotes the production of all
the major matrix proteins by fibroblasts, inhibits expres-
sion of matrix degrading plasminogen-activator inhibitor
(PAI), and increases the activity of tissue inhibitors of
metalloproteinases (TIMPS). In a rat model of progres-
sive proteinuric renal disease, interstitial Mφ produced
TGF-b , and levels correlated with interstitial inflamma-
tory infiltration [18].
MONOCYTE RECRUITMENT TO TISSUE SITES
Although interstitial Mφ proliferate in situ, their in-
crease in numbers at sites of secondary TI disease
primarily reflects the recruitment of circulating Mφ,
which largely occurs at the level of postcapillary venules
(Fig. 2). Endothelial cells (EC) and the subendothelial
environment at sites of disease variably demonstrate
constitutive, up-regulated, and de novo expression of a









3. Spreading and 
lateral migration
sLeX
GlyCAM CD62P CD62E ICAM VCAM
sLeA
CD62L
Fig. 2. An overview of monocyte trafficking: (1) selectin-mediated rolling of the leukocyte rolling on the EC surface; (2) integrin-mediated firm
adhesion to EC surface; (3) integrin-mediated spreading and migration to the EC junction; (4) integrin, PECAM-1, CD99, and JAM-1–mediated
diapedesis. Chemokines immobilized at the EC or in solution have a biological role at each step.
number of ligands that direct this process. The binding
of these molecules to counter-receptors on the surface of
Mφ promotes the phenotypic and ultrastructural changes
required for cell transmigration. There are several obli-
gate steps in this process, each of which is directed by
specific families of molecules (reviewed in [19]).
Selectin-mediated rolling
Following their initial contact with the luminal surface
of venules, the cells roll through the rapid association
and dissociation of EC selectins and Mφ counter ligands
(Fig. 2, Table 2). These interactions are strong enough to
resist shear stress, thereby slowing the cells sufficiently to
permit sampling of the rich microenvironment at the EC
surface (reviewed in [20]).
Three selectins have been identified. P-selectin is
stored preformed in Weibel-Palade bodies, and is rapidly
translocated to EC surface on activation (by proinflam-
matory cytokines or histamine); this expression is tran-
sient and decreases in minutes. E-selectin expression is
largely restricted to EC that have been activated by proin-
flammatory cytokines such as IL-1b and TNF-a; expres-
sion is delayed until de novo mRNA and protein synthesis
is complete (4–6 hours). L-selectin is constitutively ex-
pressed by most leukocytes, as well as EC. It has a central
role in normal T-cell recirculation, and is also involved in
Mφ recruitment at sites of inflammation [20].
Selectins bind carbohydrate counterligands through an
N-terminal C-type lectin domain. The ligands for E- and
P-selectin, which are constitutively expressed on Mφ, are
closely related to sialyl Lewis X (sLeX) and sialyl Lewis
A (sLeA). L-selectin can also bind these ligands and sul-
phated polysaccharides such as GlyCAM-1, MadCAM-1,
and heparan sulfate proteoglycans (HSPGs) on EC and
ECM [19].
Integrin-mediated adhesion
Integrins are heterodimeric receptors that are consti-
tutively expressed on Mφ. They are activated by confor-
mational changes triggered following ligation of recep-
tors on rolling Mφ by molecules (including chemokines)
sequestered at the EC surface (see below). The cell then
firmly adheres to the EC through interactions between
the b1 integrin, very late activation antigen-4 (VLA-4),
and the b2 integrin, leukocyte functional antigen-1 (LFA-
1), and their respective counter-receptors vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhe-
sion molecule-1 (ICAM-1). These are constitutively ex-
pressed by ECs at low levels, and heavily up-regulated
by proinflammatory cytokines such as IL-1b , interferon-
c (IFN-c), and TNF-a [19].
Transendothelial migration
Following firm adherence to EC, Mφ elongate through
extension of lamellipodium to form leading edge ad-
hesive complexes that provide traction. The cells then
crawl along gradients of chemotactic factors and adhe-
sion molecules to intercellular junctions, where there is
diapedesis to the subendothelial space. VLA-4 preferen-
tially mediates lateral migration along the endothelium
to the intercellular junction; LFA-1 primarily mediates
diapedesis [21].
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Table 2. Adhesion molecules involved in monocyte trafficking
Stage of trafficking Family Individual members CD number Ligands
Rolling Selectins P-Selectin CD62P PSGL-1, L-selectin
E-Selectin CD62E ESL-1, PSGL-1,L-selectin
L-Selectin CD62L sLex, GlyCAM-1
Firm adhesion Integrins LFA-1 CD11a/Cd18 ICAM-1
VLA-4 CD49d/CD29 VCAM-1
Transendothelial migration Integrins LFA-1 CD11a/Cd18 ICAM-1
VLA-4 CD49d/CD29 VCAM-1
Ig-SF PECAM-1 CD31 PECAM-1
JAM-1 LFA-1
Glyco- protein CD99 CD99
Subendothelial Integrins VLA-4 CD49d/CD29 FN (CS-1)
migration VLA-5 CD49e/CD29 FN (RGD)
Ig-SF PECAM-1 CD31 Basement membrane components
Abbreviations are: FN, fibronectin; Ig-SF, immunoglobulin superfamily.
The first stages of diapedesis are directed by ho-
mophilic interactions of platelet-endothelial-cell adhe-
sion molecule-1 (PECAM-1), expressed on the luminal
side of EC and intercellular junctions. Deeper pene-
tration of Mφ through the clefts between EC is then
promoted by CD99. Both PECAM-1 and CD99 are con-
stitutively expressed; this is in contrast with junctional
adhesion molecule-1 (JAM-1), a ligand for LFA-1. In qui-
escent EC, JAM-1 is exclusively localized to tight junc-
tional complexes and involved in permeability control.
On cell activation, JAM-1 is relocated to the apical as-
pect of ECs with a resultant alteration in tight junction
structure and increased permeability to leukocytes (re-
viewed in [22]).
Subsequent passage through the basal lamina is de-
pendent on contact between ECM and Mφ expressed
PECAM-1 [23]. Further interactions between VLA-4 and
VLA-5 and underlying matrix then facilitate tissue mi-
gration along a bioactive gradient [24]. While the pro-
cesses at this stage are less well characterized than those
that promote transendothelial migration, chemokines se-
questered on ECM at an increasing concentration toward
inflammatory areas have a central role.
Chemokines
Chemokines are small chemotactic cytokines that
direct leukocyte recruitment in inflammation and
homeostasis through ligation of chemokine receptors
expressed on the surface of leukocytes. To date, over
40 chemokines and 19 chemokine receptors have been
identified. Chemokines are classified by a nomenclature
(CX3CL, CXCL, CCL, and CL) that describes the rela-
tive positions of the first 2 conserved cysteine (C) residues
of the molecule to any other residue (X) in the 4 cysteine
motif common to all chemokines. This is reviewed in de-
tail elsewhere [25]. For chemokine receptors, the nomen-
clature used reflects the class of ligating chemokines: that
is, CX3CR, CXCR, CCR, and CR. Many chemokines can
bind to several different receptors within a subclass, and
receptors may bind several different chemokines. How-
ever, differential chemokine expression at inflammatory
sites and differential lineage and activation-dependent
receptor expression by leukocyte subsets confers speci-
ficity in recruitment to tissue sites.
Stimuli for the expression of inducible chemokines
are diverse and include proinflammatory cytokines (e.g.,
TNF-a, IL-1b , IFN-c), immune complexes, complement
activation products, and nonimmune stimuli such as shear
stress. Chemokines presented to circulating Mφ may be
produced by EC or originate locally from other sources;
for example, extravascular chemokines may be internal-
ized at the abluminal surface of ECs and transcytozed for
luminal presentation.
The rolling of Mφ on EC selectins may allow ex-
posure to inflammatory chemokines whose modes of
presentation and differential receptor targeting may
initiate disparate effects. For example, growth-related
oncogene-a (GRO-a/CXCL1) is immobilized on the EC
surface by HSPGs; it ligates CXCR2 to rapidly con-
vert rolling to firm adhesion by activating Mφ inte-
grins. Conversely, monocyte chemoattractant protein-1
(MCP-1/CCL2) is expressed unbound in a soluble form;
through CCR2, it mediates Mφ shape change, spreading,
and subsequent transendothelial migration [26]. Some
chemokines may act both on adhesion and chemotaxis;
for example, regulated upon activation, normal T cell
expressed and secreted (RANTES/CCL5) is presented
by EC proteoglycans, and acts through CCR1 to pro-
mote integrin-mediated firm adhesion. This chemokine
can then support Mφ spreading and shape change pri-
marily through CCR5. Subsequent transendothelial mi-
gration in response to soluble RANTES/CCL5 is then
directed by both CCR1 and CCR5 [27].
MCP-1/CCL2 and RANTES/CCL5 differentially and
selectively regulate the avidity of Mφ expressed integrins.
They induce early activation and deactivation of VLA-
4 to facilitate transendothelial diapedesis, and late and
persistent VLA-5 activation to mediate subsequent inter-
actions with matrix proteins in the basement membrane
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Table 3. Monocyte directed chemokines in situ in human secondary tubulointerstitial disease
Targeting chemokine
Chemokine CC nomenclature Source Reference receptor
MCP-1 CCL2 TEC, MNC, PTC [31–37] CCR2
MCP-4 CCL13 TEC, MNC, PTC [38] CCR2
RANTES CCL5 MNC, TEC [31, 34] CCR1, CCR5
MIP-1a CCL3 TEC [31] CCR1, CCR5
MIP-1b CCL4 TEC [31] CCR1, CCR5
IL-8 CXCL8 TEC [39] CXCR2
Abbreviations are: TEC, tubular epithelial cell; MNC, mononuclear cell; PTC, peritubular capillary; MIP, macrophage inflammatory protein.
and ECM [24]. Following migration to the subendothe-
lial space, movement along a chemokine gradient may be
facilitated by expression of matrix degradative enzymes
by Mφ. Both MCP-1/CCL2 and RANTES/CCL5 are ca-
pable of inducing this production, further amplifying the
potential for recruitment of subsequent waves of leuko-
cytes to inflammatory sites [28].
Mφ-DIRECTED ADHESION MOLECULES AND
CHEMOKINES IN SITU
Human tubulointerstitial disease
Selectins. P-selectin and E-selectin are present on
peritubular and glomerular capillaries in patients with
glomerulonephritis of various causes, but not detectable
in the tubulointerstitium or glomeruli of renal tissue ob-
tained from normal human kidneys [20]. The level of
expression in disease correlates with the extent of the
interstitial inflammatory infiltrate and degree of tubu-
lar atrophy and scar formation. L-selectin expression
by interstitial cells has been demonstrated in disease,
and correlates with the infiltration of Mφ [20]. Ligands
for L-selectin, including sLex, are found at the corti-
comedullary junction in human glomerulonephritides,
and expression relates to interstitial leukocyte infiltration
[29]. The corticomedullary junction is also a preferential
site of P- and E-selectin expression [20].
Integrins and their ligands. There is low-level expres-
sion of ICAM-1 by peritubular capillaries in normal kid-
ney. This expression is heavily increased in disease states,
with increased vascular expression and de novo expres-
sion by tubular epithelial cells; this correlates with inflam-
matory cell infiltration and the extent of tubulointerstitial
injury. Infiltrating interstitial cells also express ICAM-1
and its counterligand, LFA-1 [19].
VCAM-1 is expressed at low levels on peritubular
capillaries and tubular epithelium in normal kidneys. In
disease, this expression is increased at both sites and cor-
relates with the extent of tubulointerstitial damage and
VLA-4 expression on infiltrating leukocytes [19].
Chemokines. A number of chemokines have been
identified in secondary TI disease (reviewed in [30]). The
expression of chemokines active against Mφ is listed in
Table 3. The majority of studies have focused on MCP-1/
CCL2 and RANTES/CCL5.
MCP-1/CCL2. This chemokine is expressed by tubu-
lar epithelial cells (TEC), infiltrating monocytes, and per-
itubular capillary endothelial cells in a number of renal
diseases. Expression in situ, and in the urine of patients
with chronic progressive renal disease, correlates with
interstitial macrophage infiltration and fibrosis [31–37].
Urinary MCP-1/CCL2 is probably primarily derived from
tubulointerstitial sources in these nonproliferative dis-
eases, as glomerular tuft expression is not detected (per-
sonal observation; Fig. 3E and F). Interstitial cells have
been identified by IHC and by in situ hybridization (ISH)
to express the counter-receptor CCR2 (personal observa-
tion [40]). By dual-staining IHC, CCR2 expression in the
interstitium of nonproliferative renal disease is restricted
to Mφ (personal observation, Fig. 3G and H).
RANTES/CCL5. There is increased TEC expression
and an associated interstitial mononuclear cell inflamma-
tory infiltrate in membranous nephropathy, while in pro-
liferative glomerulonephritides, expression is predomi-
nantly confined to the glomerulus [31, 34]. The expression
of CCR5 in the interstitium of patients with either pro-
liferative or nonproliferative renal disease is restricted to
T cells. In contrast, interstitial cells expressing CCR1, an
alternative receptor for RANTES/CCL5, are predomi-
nantly Mφ, and their numbers correlate with urinary lev-
els of the chemokine [41, 42].
Animal models and secondary tubulointerstitial disease
Selectins. In a rat model of obstructive nephropa-
thy there was increased expression of P-selectin on per-
itubular capillaries and the vasa recta in the outer and
inner medulla [43]. This was associated with Mφ infil-
tration, which was significantly decreased by a blocking
antibody to P-selectin. In this study, E-selectin and sLeX-
related ligands for L-selectin were not expressed in the
obstructed kidney, although others have demonstrated an
increased expression of the L-selectin non-sLeX ligand
versican in the interstitium and peritubular capillaries in
this model [44].
Integrins and their ligands. In rodent chronic pro-
gressive proteinuric renal disease induced by puromycin
aminonucleoside (PAN), ICAM-1 expression was in-
creased in the interstitium, particularly on infiltrating
mononuclear cells [45]. In the remnant kidney and





Fig. 3. Dual staining IHC demonstrating (A)
CD68+ve macrophages, (B) CD3+ve T cells,
and (C) their colocalization, in the inter-
stitium in advanced ischemic nephropathy
(×400). The methodology utilized the 3-step
indirect IHC technique on serial sections,
initially staining for anti-CD68 (5 lg/mL;
clone PG-M1; Dako, Ltd., Ely, UK) and vi-
sualizing with DAB (brown pigment), fol-
lowed by staining for anti-CD3 (30 lg/mL
clone UCHT-1; Dako) and visualizing with
Fast Blue (blue pigment) (C). The controls
used were serial sections with the replace-
ment of either the first (B), second (A), or
both (D) antibodies with an isotype control
at the identical concentration. (E and F) Im-
munohistochemistry demonstrating MCP-1/
CCL2 expression in advanced IgA nephropa-
thy (×400). MCP-1/CCL2 is expressed pre-
dominantly by tubular epithelial expression
in chronic nonproliferative nephropathies.
There is no glomerular tuft (∗) expression, and
little glomerular epithelial expression (arrow)
[anti-MCP-1; AF-279-NA; 10 lg/mL; R&D
Systems, UK (E); isotype (F)]. (G and H)
Dual staining IHC demonstrating CCR2 ex-
pression by interstitial macrophages in mem-
branous nephropathy. CCR2 expression [anti-
CCR2; clone 5A11; 20 lg/mL; gift from
LeukoSite, Cambridge, MA; DAB (brown) vi-
sualization] (G and H) colocalizes with CD68
expression (Blue, Fast Blue visualization) to
produce black color (arrows) (H). Method-
ologies as described for 3A-D. Studies per-
formed by K. E.
obstructive models, adhesion molecule expression by
peritubular capillaries, tubular epithelial cells, and in-
filtrating leukocytes was increased [46, 47]. In the
obstructed kidney, antisense oligonucleotides predom-
inantly blocked tubular epithelial cell expression of
ICAM-1. This was associated with significantly reduced
Mφ infiltration and scar formation [47].
Tubulointerstitial ICAM-1 expression was demon-
strated in accelerated anti-GBM disease, with expression
by peritubular capillaries, tubular epithelial cells, inter-
stitial fibroblasts, and infiltrating inflammatory cells [48].
Mononuclear cells expressing LFA-1 were adherent to
ECs expressing ICAM-1 and also present at interstitial
sites. Studies on the effects of integrin/ligand blockade
have primarily concentrated on glomerular infiltration
and injury.
Chemokines.
MCP-1/CCL2. Expression patterns are similar to
those found in human disease. An overview of studies is
provided in Table 4; these consistently indicate a role in
Mφ recruitment and tubulointerstitial disease progres-
sion. Other models have provided indirect evidence by
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Table 4. Animal models of renal disease and tubulointerstitial MCP-1/CCL2, and beneficial therapeutic studies
Animal model Reference Intervention
NTS GN [49] MCP-1 blocking Ab
Mouse [50] MCP-1 knockout
Rat [51] MCP-1 blocking Ab
[52] MCP-1 OGN antisense
(Lupus GN)
MRL-Fas (lpr) mouse [53] MCP-1 knockout
NZB/W F1 mouse [54] Cyclophosphamide
Immune complex GN rat [55] Quinapril (ACE I)
Puromycin aminonucleoside nephrosis (PAN) rat [56] MCP-1 blocking Ab
Protein overload proteinuria rat [57]
[58] Anti-MCP-1 gene therapy
Hypertension 2K1C model rat [59] Valsartan (ARB)
Obstruction
Rat [60]
Mouse [61] Anti-MCP-1 gene therapy
[62] CCR2 knockout and CCR2 blockers
[63]
[64]
Subtotal nephrectomy rat [65]
[66] Protein restriction
[46] Enalapril (ACE I)
Candesartan (ARB)
[67] Lisinopril (ACE I)
(Membranous nephropathy) Heymann nephritis rat [81] Lisinopril (ACE I)
Abbreviations are: NTS, nephrotoxic serum nephritis; GN, glomerulonephritis; ACE I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker;
OGN, oligonucleotides.
demonstrating that renoprotective strategies are associ-
ated with decreased TI MCP-1/CCL2 expression and dis-
ease progression (see Table 4).
RANTES/CCL5. Increased expression is present in
acute and chronic disease [30]. Studies in obstructive
and proteinuric nephropathy indicate that infiltrating
leukocytes are a significant source of the chemokine
[61]. These investigators also found that interstitial T
cells predominantly expressed CCR5, while intersti-
tial macrophages expressed CCR1, consistent with the
findings in human renal disease [41, 42]. The use of
CCR1 knockout animals or CCR1 blockade was asso-
ciated with a reduction in both inflammatory infiltrate
and the development of fibrosis [68, 69]. Conversely,
using CCR5 knockout animals did not affect the de-
velopment of TI disease in the obstructive nephropathy
model. In the murine nephrotoxic serum model of prolif-
erative glomerulonephritis, blockade of RANTES/CCL5
decreased interstitial Mφ infiltration but not scar for-
mation, whereas blocking MCP-1/CCL2 decreased both
[49].
OTHER MECHANISMS OF MONOCYTE
RECRUITMENT IN SECONDARY TI DISEASE
Complement activation products
Activation of the complement system in situ leads to
Mφ recruitment by (1) release of C5a, which is directly
chemotactic and causes Mφ integrin activation, and (2)
production of the membrane-attack-complex (C5b-9);
this can activate resident renal cells to express proinflam-
matory cytokines and promote classic recruitment path-
ways (reviewed in [70]).
Both C3 and C5b-9 have been demonstrated in the
glomeruli of renal tissue from patients with primary
immune-mediated glomerular diseases, indicating activa-
tion of the classical pathway [70]. C5b-9 is also found at
tubular sites in these diseases, which may indicate up-
take of filtered complement components. However, the
presence of tubular C5b-9 may also represent alternative
pathway activation at this site, as despite no glomerular
expression, tubular C3 and C5b-9 is present, and C5b-9
is detected in the urine in some non-immune–mediated
renal diseases [70]. Notably, the proximal tubule has in-
herent brush border C3 convertase-like activity, and is
relatively deficient in complement inhibitory proteins.
Further, factor B, which triggers initial activation of the
alternative pathway, is expressed by tubular epithelial
cells in vitro in response to proinflammatory cytokines
[71]. Thus, essential complement proteins (such as C3)
present in glomerular filtrate in nonselective proteinuric
renal disease may be activated at this site. Also, proximal
tubular cells may generate C3 in response to cytokines
and filtered proteins or C5b-9 [71]. In human renal dis-
ease there is a correlation between tubular C5b-9 depo-
sition, interstitial Mφ infiltration, tubular atrophy, and
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Table 5. Animal models of renal disease, tubulointerstitial osteopontin, and beneficial therapeutic studies
Animal model Reference Intervention
NTS GN - rat [84] OPN OGN antisense
[85] OPN blocking Ab
(Lupus GN) - MRL-Fas (lpr) mouse [86]
Puromycin Aminonucleoside Nephrosis (PAN) rat [87]
Protein Overload Proteinuria rat [57]
Angiotensin II Infusion rat [88]
Obstruction
Mouse [89] OPN knockout
Rat [90] Angiotensinogen and AT(1) OGN antisense
[91]
Subtotal nephrectomy rat [92]
(Diabetic nephropathy) [93] Perindopril (ACE I)
Streptozotocin rat [80]
db/db mouse
Abbreviations are: NTS, nephrotoxic serum nephritis; GN, glomerulonephritis; OPN, osteopontin; ACE I, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; OGN, oligonucleotides; AT(1), angiotensin 1.
interstitial fibrosis [70]. Increased levels of urinary C5b-
9 levels in immune-mediated human renal diseases are
associated with a worse clinical prognosis [72].
Animal models support these data. In murine immune
complex–mediated glomerulonephritis, the absence of
the C5a receptor was associated with significantly re-
duced interstitial mononuclear cell infiltrate and injury
[73]. There was no difference in glomerular pathology.
A previous study using a similar model had showed that
absence of C5 attenuated both glomerular and TI disease
[74]. These observations indicate a role for C5b-9 forma-
tion in glomerular injury and for C5a, through recruit-
ment of mononuclear cells, in TI disease. In nonimmune
renal disease, however, C5b-9 has a more important role
in interstitial Mφ recruitment. The use of C6 knockout
animals in the PAN and remnant kidney models was as-
sociated with reduced interstitial inflammation and TI
injury [75, 76]. The absence of C6 prevents the forma-
tion of C5b-9 but not other upstream components, such as
C5a. This same group had previously demonstrated in the
PAN model that inhibiting tubular expression of the com-
plement regulatory protein Crry by antisense oligonu-
cleotides augmented tubulointerstitial injury [77].
Macrophage-colony stimulating factor-1 (M-CSF)
M-CSF promotes the differentiation and proliferation
of bone marrow–derived monocytes to mature Mφ, and
is also a potent Mφ chemoattractant. It also augments the
proinflammatory and cytotoxic response of Mφ to stim-
uli [78]. De novo expression of M-CSF protein in human
renal disease has been demonstrated by IHC. Glomeru-
lar expression is restricted to mesangial cells in glomeru-
lonephritides, with the highest levels in proliferative
disease [79]. This expression correlates with local Mφ
infiltration, proliferation, and activation. In both
glomerular and nonglomerular renal disease there is de
novo expression of M-CSF by proximal and distal TECs,
which also correlates with local Mφ infiltration and pro-
liferation [79].
The expression of M-CSF in animal models of immune
and nonimmune renal disease is consistent with human
disease [80, 81]. Direct evidence of a role for M-CSF
in vivo has been recently published. Using the unilat-
eral ureteric obstruction model of progressive renal dis-
ease, mice deficient of M-CSF or treated with an M-CSF
receptor-blocking antibody had significantly reduced in-
terstitial Mφ infiltration and proliferation and tubular
injury compared to control animals [78].
Osteopontin
Osteopontin is a secreted phospho-glycoprotein with a
diverse range of biological roles, including modulation of
Mφ function (reviewed in [82]). In vitro it is a chemoat-
tractant and adhesion molecule for Mφ. In vivo, a Mφ
infiltrate accumulates at the site of dermal injection of
osteopontin in rodents. In humans, there is some consti-
tutive expression by distal tubular cells in normal kid-
ney. Increased expression at these sites and de novo ex-
pression by proximal TEC occurs in glomerulonephritis
and correlates with the extent of Mφ infiltration [83]. A
number of animal models have been used to demonstrate
the association between increased TEC osteopontin ex-
pression and interstitial inflammation, and there is direct
evidence of a role in Mφ recruitment in some studies
(Table 5).
The effects of osteopontin on Mφ are mediated
through numerous receptors, including b1, b2, and b3
integrins, and isoforms of the hyaluronic acid receptor
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CD44 [82]. Post-translational modification of osteopon-
tin is common, and may be important in determining its
biological effects. Cleavage of osteopontin by thrombin,
which is likely to occur at sites of inflammation, reveals
Mφ binding sites, and also releases chemotactic frag-
ments. Interactions between the C-terminal domain of
osteopontin and isoforms of the receptor CD44 induces
Mφ chemotaxis, and interactions between the nonover-
lapping N-terminal domain, revealed by thrombin cleav-
age, and beta(3)-integrins, leads to Mφ spreading and
activation [82].
T cells
T cells expressing activation markers infiltrate the
interstitium and colocalize with Mφ in disease, but
their role in the progression of tubulointerstitial injury
is not clearly defined (personal observation [94], see
Fig. 3A to D). Animal models using T-cell deplete animals
developed the same amount of interstitial Mφ accumula-
tion and TI injury as T-cell replete controls [13–15]. More
recent evidence has shown that activated T cells express
proinflammatory cytokines that induce TEC expression
of Mφ-directed chemokines, such as MCP-1/CCL2 and
RANTES/CCL5 [95]. This response is augmented in part
by binding of TEC CD40 by T-cell CD40-ligand (CD40L).
In an animal model of nonimmune progressive protein-
uric renal disease, blocking CD40-CD40L interactions
was associated with a significant reduction in both inter-
stitial Mφ recruitment and the development of tubuloin-
terstitial injury [96].
CD4+ T cells predominate over CD8+ T cells
at interstitial sites in the majority of progressive
chronic renal diseases, although there is some variation
(Table 1). Harris et al have shown that these subsets
may have disparate roles. In the adriamycin nephropathy
model of nonimmune progressive proteinuric renal dis-
ease, CD8+ T-cell depletion was associated with reduced
Mφ infiltration and tubulointerstitial injury, whereas the
converse occurred when CD4+ T cells were depleted
[97, 98].
Inflammatory lipids
Kees-Folts et al demonstrated the presence of a lipid
chemotactic for Mφ in the urine of rats with protein-
overload–induced proteinuria [99]. This lipid was de-
rived from the tubular metabolism of albumin-borne fatty
acids. Indeed, BSA depleted of bound fatty acids induced
less interstitial inflammation and TI injury than lipid re-
plete BSA [100]. In minimal change disease, urinary al-
bumin is relatively depleted of fatty acid, and this has
been proposed as an explanation for the absence of in-
terstitial injury in this condition [101]. An inflammatory
lipid has not been identified in human progressive pro-
teinuric renal disease to date, however; observations in
animal studies may relate to the heterogeneous albumin
and not provide an explanation for the development of
human disease.
Recently, urinary levels of liver-type fatty acid–binding
protein (L-FABP), an intracellular carrier protein of free
fatty acids (FFA) expressed in the proximal tubule of
human kidney, have been shown to predict renal disease
progression [102]. It is not clear if these findings reflect
increased FFA tubular load, or if this is another marker
of proteinuria-induced tubular injury.
The renin-angiotensin-system
There are several direct proinflammatory effects of
renin-angiotensin-system (RAS) activation. Angiotensin
II (Ang II) is directly chemotactic for Mφ, increases ad-
hesion molecule expression on ECs and proximal TECs,
and induces MCP-1 and osteopontin expression in situ
[103, 104]. Mφ chemotaxis and activation may also occur
as a consequence of proximal TEC expression of TNFa,
macrophage migration inhibitory factor (MIF), and reac-
tive oxygen species in response to Ang II [104]. Ang II
can also activate Mφ directly to express proinflammatory
cytokines and reactive oxygen species [105]. All of these
effects are mediated through angiotensin II receptor type
1 (ATR1).
In the normal physiologic state, renal renin activity is
restricted to the juxtaglomerular apparatus. It acts on
circulating angiotensinogen to promote the systemic re-
lease of Ang II. In the subtotal nephrectomy model there
was also de novo renin activity by TEC, which colocal-
ized with increased Ang II production [106]. ACE inhi-
bition reduced tubular renin activity, Ang II production,
and tubulointerstitial injury, indicating that tubular RAS
activity promotes disease progression. Indeed, proximal
TECs can synthesize all the components of the RAS, re-
sulting in high concentrations relative to plasma of Ang
II in proximal tubular luminal fluid [107]. This has been
observed in both human disease and animal models [91,
106, 108].
Macrophages can synthesize all RAS components
[109]. Interstitial Mφ in the subtotal nephrectomy model
expressed Ang II and ATR1, indicating a potential feed-
back mechanism that promotes Mφ recruitment and ac-
tivation [110].
In chronic renal disease, hyperaldosteronism is often
present as a consequence of adrenal secretion in response
to changes in potassium homeostasis, induced by renal
injury. Local production of aldosterone has not been de-
scribed, in contrast to cardiac disease, where there is sig-
nificant in situ generation (reviewed in [111]). The in-
flammatory effects of aldosterone include increased renal
expression of proinflammatory cytokines, such as osteo-
pontin and MCP-1/CCL2, with interstitial Mφ infiltration
and tubular injury [112]. Some of the beneficial effects






















Fig. 4. Proteinuria theory. Schemata of mechanisms by which proteinuria promotes Mφ recruitment to the interstitium.
of ACE inhibition may be through reduction of serum
aldosterone levels [111]. Clinical studies are assessing if
combined ACE and aldosterone inhibition confers ad-
ditional benefit. This has already been demonstrated in
cardiac disease [111].
What mechanisms link Mφ recruitment and
tubulointerstitial disease progression?
Three major mechanisms of progressive tubulointersti-
tial injury have been proposed. Their promotion of Mφ
recruitment and activation may provide an important link
between the trigger for injury and the establishment of
progressive damage.
Proteinuria. All low-molecular-weight (MW) proteins
(<40 kD) and a fraction of intermediate MW proteins
(40–100 kD), such as albumin, pass across the glomeru-
lar basement membrane into the urinary space (reviewed
in [113]). Under normal physiologic conditions, very lit-
tle protein is detected in the urine due to highly effi-
cient reabsorption by proximal tubular epithelial cells.
However, in glomerular disease, loss of basement mem-
brane integrity increases leakage of intermediate MW
proteins, and high MW proteins also begin to cross
the basement membrane. Thus, tubular epithelial cells
are both exposed to higher concentrations and endo-
cytoze a different repertoire of proteins. This protein
overload exceeds the normal reabsorptive capacity of
these cells and affects their functional integrity with di-
rect biological consequences, including the recruitment
and activation of mononuclear cells by several pathways
(Fig. 4): (1) in vitro proximal TECs express Mφ-directed
chemokines in response to high concentrations of pro-
teins of intermediate-molecular-weight, including albu-
min and transferrin [114, 115]. Further, in human disease,
urinary levels of chemoattractants have been correlated
with the degree of proteinuria [37]. Interventions that de-
crease proteinuria in animal models of disease are associ-
ated with reduced tubular uptake of protein, chemokine
expression, and inflammation (Table 4); (2) in response
to an increasing protein uptake, there is increased tubu-
lar cell production of ammonia, which may directly in-
crease tubular C3 convertase activity and so generate Mφ
chemoattractants and other complement activation prod-
ucts [70]. Urinary levels of complement activation prod-
ucts correlate with the degree of proteinuria in a range of
renal diseases [70]; and (3) urinary proteins activate TEC
production of angiotensinogen and ACE with subsequent
increased local production of Ang II [116]. In addition to
inflammatory effects that promote Mφ recruitment (see






















Fig. 5. Hypoxia theory. Schemata of mechanisms by which hypoxia promotes Mφ recruitment to the tubulointerstitium, which, in turn, exacerbates
tissue hypoxia.
above), Ang II is best known as a potent vasoconstrictor.
This may lead to glomerular hypertension in previously
unaffected nephrons. These glomeruli would ultrafiltrate
protein and potentiate the chemotactic potential of TEC
[117].
The demonstration of causation of Mφ recruitment
and tubulointerstitial disease by proteinuria requires
study in isolation from other biological effects: this is
currently not possible in humans. The animal model
that approaches this requirement is the protein-overload
proteinuria model. There is concern, however, that the
disease induced is related to factors peculiar to the
heterogeneous albumin used (see above), although ex-
periments that characterized the model found that ho-
mologous protein also induced disease [13].
It is also unclear why patients with minimal change
nephropathy do not develop tubulointerstitial disease.
This may relate to the selectivity of proteinuria in this
disease, as high MW proteins, such as complement, are
not leaked. Also, the fatty load of the albumin in MCN
is relatively small [101]. These observations may indicate
the differential nephropathic effect of different proteins
(reviewed in [113]).
Chronic hypoxia. In the development of interstitial fi-
brosis and tubular atrophy, reduced capillary density may
promote tissue hypoxia through increasing the effective
distance of oxygen transport. The development of inter-
stitial scarring may further exacerbate hypoxia by impair-
ing the diffusion gradient of oxygen. With the generation
of ROS by resident renal cells in response to ischemia,
proximal TEC and interstitial fibroblasts respond by pro-
moting ECM deposition with subsequent scar formation
[118]. Hypoxia can also directly induce tubular cell apop-
tosis. Futrakul et al have demonstrated an inverse corre-
lation between peritubular capillary blood flow and tubu-
lointerstitial disease [119].
Our understanding of the processes that reduce cap-
illary density and blood flow is incomplete (reviewed in
[120]). Putative mechanisms include (Fig. 5): (1) vasocon-
striction promoted directly by Ang II and endothelin I, or
indirectly through loss of vasodilator tone through down
regulation of nitric oxide; (2) mechanical obstruction to
flow by primary glomerular diseases and obliteration of
the glomerular capillary bed; and (3) changes in local ex-
pression of angiogenic growth factors, such as vascular
endothelial growth factor (VEGF), during the progres-
sion of damage.
Activation of RAS and increased adhesion molecule
expression by EC and TEC in response to hypoxia may
directly promote Mφ recruitment [120]; hypoxia may
then augment the activation of Mφ at tissue sites [121].
Recruited Mφ may themselves promote a hypoxic en-
vironment; Mφ colocalize with tubular cells at sites of
VEGF down-regulation, and in vitro, Mφ-derived cy-
tokines down-regulate tubular VEGF expression [122].
There is de novo interstitial Mφ and increased TEC ex-
pression of thrombospondin-1 (TSP-1) in models of renal
disease [122]. This glycoprotein inhibits the proliferation
of EC and can induce their apoptosis. In addition to its an-
tiangiogenic effects, it activates locally expressed TGF-b
and facilitates the Mφ uptake of apoptotic cells [123].
For hypoxia to be a primary stimulus for the ini-
tiation and progression of renal disease, evidence is
required that tubulointerstitial ischaemia precedes the






















Fig. 6. Glomerular cytokine theory.
Schemata of the 4 mechanisms by which
glomerular-derived cytokines reach the
tubulointerstitium, where they may then
promote Mφ recruitment (see text).
development of inflammation and injury [120]. Also,
Futrakul et al found reduced interstitial perfusion in
patients with progressive forms of nephrotic syndrome
prior to the development of TI disease, whereas per-
fusion was maintained in minimal change nephropa-
thy [119]. In certain renal diseases interstitial ischemia
may localize initially to nephrons selected through
involvement of their glomeruli in focal disease. Mφ re-
cruited to these nephrons will then exacerbate local hy-
poxia and involve the tubules of bystander nephrons, the
glomeruli of which may then be exposed to compensatory
hemodynamic changes. Angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) may work in part through improving intersti-
tial perfusion by antagonizing the vasoactive effects of
Ang II. Recent in vivo experiments support this theory
[124].
Glomerular-derived cytokines. These are synthesized
by resident glomerular cells or infiltrating leukocytes (re-
viewed in [125]), and disperse to tubulointerstitial sites
by several routes (Fig. 6): (1) via glomerular filtrate to
activate tubular epithelial cells; (2) through the renal
microvasculature to activate endothelial and suben-
dothelial cells; (3) through direct communication be-
tween the glomerular tuft and Bowman’s capsule and
periglomerular tubulointerstitium; (4) through glomeru-
lar tuft lesions that breach the parietal epithelium to lie
outside Bowman’s capsule. Glomerular filtrate is then
misdirected, passing outside Bowman’s space to surround
the glomerulus and extend along the outer aspect of the
proximal tubule to subepithelial peritubular spaces [126–
128].
TNF-a, IL-1b , and IFN-c promote glomerular
inflammation and injury and associated tubulointersti-
tial disease in experimental models of proliferative re-
nal disease (reviewed in [129]). In human proliferative
glomerulonephritis, infiltrating and/or resident cells pro-
duce these cytokines [129]. There are little data on their
expression in situ in chronic glomerular disease, although
there is a significant increase in urinary levels in both
membranous and IgA nephropathy [130, 131].
The evidence for proinflammatory cytokines and other
inflammatory products of glomerular injury in the de-
velopment of secondary TI disease includes: (1) IL-1b
increases tubular osteopontin expression, and treatment
with an IL-1 receptor antagonist in experimental models
of glomerulonephritis ameliorated glomerular injury and
reduced tubulointerstitial ICAM-1 expression and leuko-
cyte infiltration [132]; (2) TGF-b and Ang II, which are
both produced at glomerular sites, increase tubular osteo-
pontin and TNF-a expression, respectively [104, 133]; (3)
glomerular-derived chemokines may be taken up at the
luminal surface by tubular epithelial cells and processed
and presented on their basal surface, and/or, in the case
of MCP-1/CCL2, increase tubular adhesion molecule and
cytokine expression [134]; (4) in response to nephron loss,
there is increased glomerular expression of proinflam-
matory molecules, including MCP-1/CCL2, TGF-b , and
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adhesion molecules in response to mechanical forces such
as shear stress. Soluble mediators produced in this setting
may then have downstream effects [3].
Interstitial macrophage phenotype and function
As interrupting Mφ recruitment in vivo ameliorates
injury in animal models of renal disease, we can infer a
proinflammatory Mφ phenotype in these settings. How-
ever, Mφ also play an important role in tissue repair and
remodeling. In this context, local factors are important
in determining the phenotype adopted by recruited Mφ.
For example, transgenic mice whose islet cells expressed
MCP-1/CCL2 developed a Mφ insulitis. However, this
infiltrate did not promote islet cell destruction, and dia-
betes mellitus did not develop [135]. Thus, one or more
factors necessary for the adoption of a proinflammatory
Mφ phenotype able to promote tissue injury were absent
in this model.
These observations are supported by in vitro stud-
ies. Treatment with proinflammatory cytokines, including
TNF-a and IFN-c, result in Mφ adopting a ‘classic’ ac-
tivated phenotype. These cells are functionally cytotoxic
and express NO, ROS, and proinflammatory cytokines
and chemokines (reviewed in [136]). There is also in-
creased expression of HLA class II and CD86. Chemo-
tactic factors involved in Mφ recruitment, including
MCP-1/CCL2, RANTES/CCL5, OPN, and Ang II also
increase Mφ cytotoxicity and proinflammatory cytokine
expression [28, 82, 105, 137, 138]. Hypoxia may further
augment this response [121].
Treatment with anti-inflammatory cytokines, including
IL-4, IL-10, and IL-13, results in ‘alternatively’ activated
Mφ [136]. This phenotype is associated with the preferen-
tial expression of anti-inflammatory cytokines, including
IL-10 and IL-1 receptor antagonist (IL-1ra), and the cell
surface molecules Mannose receptor and Scavenger re-
ceptor. These cells scavenge cellular debris, and promote
angiogenesis and tissue remodeling and repair. Recently,
a ‘type II activated’ phenotype has also been described
[139]. This occurs on exposure of Mφ to classic proinflam-
matory cytokines in the presence of immune complexes;
ligation of FCcR prevents the adoption of a ‘classic’ phe-
notype, but results in one similar to that observed in the
‘alternatively activated’ Mφ.
Other phenotypic markers have been characterized
primarily from work using mice [140]. These include FccR
I, II, and III, whose expression is increased when Mφ are
classically activated, and have been used in the study of
Mφ phenotype in human liver disease [141]. The LPS re-
ceptor is also highly expressed on classically activated Mφ
in vitro and in vivo [140]. However, analysis of antigenic
markers of phenotype by IHC in human renal disease is
of limited use because most are not restricted to a specific
Mφ phenotype, and are also expressed by other immune
and nonimmune cells.
There is also variation in cell surface antigen ex-
pression depending on the tissue site of Mφ [140]. For
example, interstitial, but not glomerular, Mφ express per-
oxisome proliferator-activated receptor-c (PPARc) in di-
abetic nephropathy, and CCR5 in glomerulonephritides
[42, 142].
Important information on Mφ phenotype has come
from ex vivo analyses. Rees et al have used functional
assays on isolated glomerular Mφ to confirm that the
‘classically’ activated phenotype predominates in some
animal models of glomerular disease [143]. It is more dif-
ficult to directly characterize the phenotype of interstitial
Mφ. An increase in expression of proinflammatory over
anti-inflammatory cytokines in the tubulointerstitium has
not been demonstrated to date, but because the presence
of Mφ at interstitial sites is associated with cell injury, a
‘classic’ activated phenotype is believed to predominate.
However, there is recent evidence for functional het-
erogeneity of glomerular and interstitial Mφ in vivo [136].
The phenotypic profile of Mφ isolated from the glomeruli
in models of proliferative glomerulonephritis depends on
the stage of the disease when isolated. Within the intersti-
tium of nonglomerular disease, such heterogeneity may
also be important in determining disease outcome. The
migration of Mφ through matrix is facilitated by the fix-
ation of urokinase-type plasminogen activator (uPA) to
the cell surface by its receptor uPAR (or CD87); uPA
promotes local degradation of matrix proteins by the gen-
eration of plasmin. Also, Mφ-expressed uPAR, through
interactions with scavenger receptors, is involved in the
scavenging and degradation of profibrotic cytokines and
matrix proteins. Using an obstructive uropathy model,
Zhang et al have demonstrated that interstitial Mφ may
adopt a disease regulatory phenotype [144]. They showed
that uPAR knockout animals had reduced interstitial in-
flammation but increased fibrosis. Although these data
should be interpreted with care, because TECs also ex-
pressed uPAR, they may indicate an important antifi-
brotic and reparative role for a proportion of interstitial
Mφ in TI disease.
Determining the effects of a specific Mφ-derived gene
product on TI disease progression is now possible using
the methodology of bone marrow transplantation with
genetically engineered stem cells. Nishida et al used this
technology to study the role of the Mφ expression of the
Ang II receptor ATR1 in the murine model of obstruc-
tive nephropathy [145]. Although its absence on bone
marrow–derived cells did not alter the early stages of dis-
ease progression, it was associated with reduced inter-
stitial Mφ infiltration at latter stages. Paradoxically, this
was associated with increased scar formation. As ATR1-
deficient Mφ have reduced phagocytic activity, these
results imply that Ang II may promote a scavenging
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phenotype of a significant proportion of interstitial Mφ
in the latter stages of disease, which is important in the
clearance of matrix and apoptotic cells.
Other noncytokine-associated receptors may also have
a role in directing Mφ phenotype. The PPARc is a mem-
ber of the nuclear receptors of ligand-activated tran-
scription factors. It is highly expressed in adipose tissues,
where it is involved in lipid metabolism and homeostasis.
It is also expressed on Mφ, and receptor ligation down-
regulates the response of the cell to classic proinflamma-
tory cytokines and promotes the adoption of a scavenger
phenotype [146]. The thiazolidinedione group of drugs
used in the management of diabetes mellitus in humans is
PPARc agonists. However, when used in an animal model
of glomerulonephritis, they had a proinflammatory effect
[147].
Therapeutic strategies targeting interstitial inflammation
in secondary TI disease
Results from clinical trials have identified that disease
progression can be significantly slowed with aggressive
blood pressure control and RAS blockade. A significant
proportion of patients, however, still progress to end-
stage renal disease despite this approach. These current
therapeutic strategies work primarily by counteracting
the adverse glomerular haemodynamic changes that oc-
cur in disease progression. New approaches may target
the development of interstitial inflammation; some of
these therapies will directly target Mφ. The majority of
studies of novel biological agents to date have focused
on glomerular disease. A benefit in secondary tubuloin-
terstitial disease can be inferred from some of these. We
have focused on therapies that directly relate to the areas
discussed in this review.
Chemokine receptor antagonists
There has been a massive biotechnology investment in
the development of chemokine receptor antagonists (re-
viewed in [148]). Their use in animal models of progres-
sive renal disease has yielded encouraging results [64, 68,
69]. However, major challenges have been encountered
in their development for human disease; they are closely
related to other G protein–coupled receptors, leading to
cross reactivity in biological effects. Also, species differ-
ences in the expression of chemokines and their recep-
tors make interpretation of results from experiments with
animal models difficult. In addition, conformational dif-
ferences in receptors may mean that antagonists that
function well in vitro may not be efficacious in vivo.
Animal models studying the role of chemokine re-
ceptors in glomerulonephritides have highlighted a fur-
ther layer of complexity. Models of anti-GBM disease
in mice deficient of the chemokine receptor CCR1 or
CCR2 were demonstrated to exacerbate disease [149,
150]. Also, in an immune-complex model of glomeru-
lonephritis, CCR5 blockade aggravated glomerular in-
jury even though leukocyte infiltration was reduced [151].
In this case, partial agonistic effects of the molecule pro-
moted a proinflammatory phenotype of recruited Mφ.
Further, resident renal cells have been demonstrated to
express chemokine receptors, making such studies diffi-
cult to interpret. Their function on nonimmune cells is
not yet defined, but if they have an important homeo-
static role, their targeting could promote injury in some
settings.
Complement blockade
These may have a significant therapeutic impact on
a wide range of human diseases, including the manage-
ment of both acute immune-mediated glomerular injury
and chronic progressive proteinuric disease (reviewed
in [70]). Complement receptor 1–related gene/protein y
(Crry) is a naturally occurring cell-bound peptide that in-
hibits C3/C5 convertase activity. Recombinant technol-
ogy has led to a soluble incarnation (Crry-Ig), which, on
prolonged use in a murine model of lupus nephritis, ame-
liorates glomerular and interstitial disease [152]. The hu-
man corollary of Crry-Ig is soluble complement receptor
1 (sCR1). It is well tolerated by humans, but has not been
studied in human renal disease [70].
Complement-specific blocking antibodies are also at
an advanced stage of development. Anti-C5 monoclonal
antibodies prevent the formation of C5a and C5b-9, and
prolonged use in a murine model of lupus disease with
nephritis was beneficial [153]. Humanized anti-C5 mono-
clonal antibodies have been developed and are at an early
stage of evaluation in the management of lupus in humans
and in membranous nephropathy [70]. The rationale for
their use in nonimmune disease has been explored above.
Optimal RAS blockade
Numerous animal models (see Tables 4 and 5) and
clinical trials have demonstrated the beneficial effects of
RAS blockade. The more effective the blockade of RAS,
the greater the clinical benefit. Patients on ACEIs who
achieve a lower blood pressure, significant proteinuria re-
duction, and demonstrate an early increase in creatinine
(of up to 30%) as a marker of decreased intraglomerular
pressure have a better renal prognosis than those who do
not [154]. There is now increasing evidence for the con-
comitant use of ACE inhibitors and ARBs [155]. Long-
term trials are needed to define the role of drugs that
antagonize the effects of aldosterone [111].
Mycophenolate mofetil
Mycophenolic acid (MPA), the bioactive form of
the molecule, was primarily developed to inhibit the
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proliferation of T cells, and is used in the prophylaxis
of allograft rejection. MMF also directly inhibits the pro-
liferation of Mφ and resident renal cells. Thus, it may
have a potential role in other clinical settings [156]. In
animal models of nonimmune renal disease, it arrests pro-
gression through inhibiting development of secondary TI
disease.
MMF was renoprotective in the subtotal nephrectomy
model of progressive disease [157]. The treatment signif-
icantly reduced interstitial Mφ and T-cell numbers and
scar formation. Through reducing interstitial inflamma-
tion MMF also attenuates the adverse glomerular haemo-
dynamics changes that occur after subtotal nephrec-
tomy. When commenced shortly after the induction of
injury, MMF did not completely prevent interstitial Mφ
infiltration and scar formation. However, in combina-
tion with a RAS blocker, TI inflammation and injury
was almost completely prevented, and even when used
in established disease, progression was significantly in-
hibited [158]. MMF was also renoprotective in other
models of nonimmune renal disease, including Ang
II infusion, NO synthase inhibition, genetic hyperten-
sion, adriamycin, and protein overload proteinuria [159–
163]. Randomized controlled trials are required to
demonstrate beneficial effects of MMF in human non-
immune native progressive renal diseases.
Gene therapy
The complexity of the kidney poses particular chal-
lenges for targeted and efficient gene transfer to a specific
cell type (reviewed in [164]). Antisense oligonucleotide
(ODN) technology involves the construction of short
fragments of nucleic acid whose sequences are compli-
mentary to specific mRNA. When delivered into the cell,
it blocks the translation of the targeted mRNA to pro-
tein (reviewed in [165]). ODNs are attractive therapies
because: (1) they do not require a viral vector, which has
associated risks; (2) they can be administered into a pe-
ripheral vein; (3) they are accumulated and active in prox-
imal TECs. Okada et al used specific ODNs in a rodent
model of proliferative glomerulonephritis to inhibit prox-
imal TEC expression of MCP-1/CCL2 and OPN. This was
associated with decreased Mφ recruitment to the inter-
stitium [52, 166]. ODN technology has also been success-
fully used in a model of obstructive uropathy, where it
reduced proximal TEC ICAM-1 expression and associ-
ated interstitial inflammation and scar formation [47].
The effects of a single dose are relatively short lived (sev-
eral weeks), which may have implications for the man-
agement of chronic progressive renal disease [164].
A newly developed kidney-targeted naked plasmid
transfer technique has enabled successful gene transfer
into interstitial cells with stable and long-term (months)
expression. A gene coding the expression of the protein
7ND, which complexes and inactivates MCP-1/CCL2, has
successfully attenuated Mφ recruitment to the intersti-
tium and TI injury in the protein overload model of
chronic renal disease [58].
When systemic delivery of a therapeutic protein is re-
quired, skeletal muscle–targeting gene therapy is a partic-
ularly attractive technique. It is a relatively easy, cheap,
and efficient means of gene transfer to facilitate stable
and long-term release of the chosen protein. Such a sys-
tem has been used successfully in an animal model of
ichemic-reperfusion injury of the kidney and obstructive
uropathy [63].
Once a Mφ is committed to a particular phenotype,
that cell cannot be reprogrammed by its local envi-
ronment [136]. Manipulating the microenvironment first
encountered by an uncommitted Mφ on entering the kid-
ney, or directing the phenotype of Mφ before they in-
filtrate the kidney are interesting therapeutic concepts
[129]. Indeed, genetically modified Mφ, programmed
to express the anti-inflammatory cytokine IL-1ra, local-
ized to the kidney, and ameliorated interstitial inflamma-
tion and damage in an obstructive nephropathy model
[167]. Such techniques have also been successfully used
in reducing glomerular injury in models of proliferative
glomerulonephritis [168].
CONCLUSION
We now have substantial knowledge of the role of the
Mφ in promoting secondary TI inflammation and injury.
This has led to targeting by novel therapies. However,
these approaches in animal models now require careful
demonstration of efficacy in human disease. Also, fur-
ther study is needed to elucidate potential targets that
direct the trafficking of Mφ. Extended analysis of the
interactions between Mφ and resident tissue cells and
matrix, and the effect of the phenotype adopted by the
infiltrating cell on tissue repair may further direct our
approach to the management of established disease.
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